Skip to content

Examination of the Effects of a Functional Food on Blood Flow and Cold Sensitivity: An Open Trial.

Examination of the Effects of a Functional Food on Blood Flow and Cold Sensitivity: An Open Trial. - Examination of the Effects of a Functional Food on Blood Flow and Cold Sensitivity: An Open Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000042012
Enrollment
24
Registered
2020-10-07
Start date
2020-10-08
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

N/A (healthy adults)

Interventions

[1]A cold stress test. [2]Measurement. [3]Oral intake of the test food (3 capsules in a day
4 weeks). [4]A cold stress test. [5]Measurement.

Sponsors

TES Holdings Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: [1]Healthy Japanese females aged 30-49 years. [2]Individuals who are healthy and have no chronic physical disease. [3]Individuals who are aware of being sensitive to cold. [4]Individuals whose written informed consent has been obtained. [5]Individuals who can have an examination on a designated check day. [6]Individuals judged appropriate for the study by the principal.

Exclusion criteria

Exclusion criteria: [1]Individuals using medical products. [2]Individuals who are patient or have a history of psychiatric disease, high blood pressure, diabetes, and hyperlipidemia. Individuals who use a drug for treatment of disease. [3]Individuals who use a drug to treat a disease in the past 1 month. [4]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease. [5]Individuals who are a patient or have a history of or endocrine disease. [6]Individuals whose menstruation is irregular (individuals whose menstruation cycle must be 28 +- 2 days). [7]Individuals whose BMI is less than 18.5kg/m2 or over 25kg/m2. [8]Individuals with serious anemia. [9]Individuals who are a smoker. [10]Individuals with inflammation and scratch at fingers. [11]Individuals who have excessive alcohol intake more than 60 g in a day of pure alcohol equivalent. [12]Individuals who have allergic reaction to ingredients of test foods and other foods or drugs. [13]Individuals with possible changes of life style during the test period. [14]Individuals who have a habit to use Foods with Function Claims, functional foods and/or supplements claiming to improve cold sensitivity, blood flow, blood pressure, and thermal comfort effect in the past 3 months and/or are planning to use those foods during test periods. [15]Individuals who are or are possibly, or are lactating. [16]Individuals who participated in other clinical studies in the past 3 months. [17]Individuals who are or whose family is an employee of a health food, functional food, or cosmetic company. [18]Individuals judged inappropriate for the trial by the principal.

Design outcomes

Primary

MeasureTime frame
[1]Indexes for effectiveness (blood flow measurement with laser doppler(1), skin surface temperature measurement with thermography(1), image instrumentation of capillary vessel(2), Subjective questionnaire(1). (1)Screening, Week 4: before the cold stress test, just after the cold stress test, 2 min. after the cold stress test, 4 min. after the cold stress test, 6 min. after the cold stress test, 8 min. after the cold stress test, 10 min. after the cold stress test. (2)Screening, Week 4: before the cold stress test.

Secondary

MeasureTime frame
*Safety indexes [1]Blood pressure, pulsation(1) [2]Weight, body fat percentage, BMI(1) [3]Axillary temperature(1) [4]Hematologic test(1) [5]Blood biochemical test(1) [6]Urine analysis(1) [7]Doctor's questions(1) [8]Side effects and adverse events(2) [9]Subject's diary(3) (1)Screening, Week 4: before the cold stress test. (2)Week 4: before the cold stress test. (3)each day from Screening and one day before the Week 4.

Countries

Japan

Contacts

Public ContactRyoma Shimizu

TES Holdings Co., Ltd. Administrative Department of Clinical Trials

r.shimizu@tes-h.co.jp+81-3-6801-8480

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026